IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v26y2025i2d10.1007_s10198-024-01702-1.html
   My bibliography  Save this article

A budget impact analysis of a digital monitoring solution in patients treated with oral anticancer agents: a medico-economic analysis of the randomized phase 3 CAPRI trial

Author

Listed:
  • Etienne Minvielle

    (Division of Interdisciplinary Patient Care Pathways (DIOPP)
    I3-CRG, Ecole polytechnique -CNRS (French National Centre for Scientific Research), Institut polyetchnique de Paris)

  • Henri Leleu

    (Public health expertise)

  • Marc Masseti

    (Public health expertise)

  • Arlindo Ferreira

    (Resilience
    Universidade Católica Portuguesa)

  • Gérard Pouvourville

    (ESSEC Business School)

  • Mario Di Palma

    (Division of Interdisciplinary Patient Care Pathways (DIOPP))

  • Florian Scotté

    (Division of Interdisciplinary Patient Care Pathways (DIOPP))

Abstract

Background/Objectives Remote patient monitoring (RPM) has demonstrated numerous benefits in cancer care, including improved quality of life, overall survival, and reduced medical resource use. This study presents a budget impact analysis of a nurse navigator-led RPM program, based on the CAPRI trial, from the perspective of the French national health insurance (NHI). The study aimed to assess the impact of the program on medical resource utilization and costs. Methods Medical resource utilization data were collected from both medico-administrative sources and patient-reported questionnaires. Costs were calculated by applying unit costs to resource utilization and estimating the average monthly cost per patient. Sensitivity analyses were conducted to explore different perspectives and varying resource consumption. Results The analysis included 559 cancer patients participating in the CAPRI program. From the NHI perspective, the program resulted in average savings of €377 per patient over the 4.58-month follow-up period, mainly due to reduced hospitalizations. The all-payers perspective yielded even greater savings of €504 per patient. Sensitivity analyses supported the robustness of the findings. Conclusion The budget impact analysis demonstrated that the CAPRI RPM program was associated with cost savings from the perspective of the NHI. The program’s positive impact on reducing hospitalizations outweighed the additional costs associated with remote monitoring. These findings highlight the potential economic benefits of implementing RPM programs in cancer care. Further research is warranted to assess the long-term cost-effectiveness and scalability of such programs in the real-world settings.

Suggested Citation

  • Etienne Minvielle & Henri Leleu & Marc Masseti & Arlindo Ferreira & Gérard Pouvourville & Mario Di Palma & Florian Scotté, 2025. "A budget impact analysis of a digital monitoring solution in patients treated with oral anticancer agents: a medico-economic analysis of the randomized phase 3 CAPRI trial," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 26(2), pages 267-273, March.
    • Handle: RePEc:spr:eujhec:v:26:y:2025:i:2:d:10.1007_s10198-024-01702-1
    DOI: 10.1007/s10198-024-01702-1
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-024-01702-1
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-024-01702-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Olivier Mir & Marie Ferrua & Aude Fourcade & Delphine Mathivon & Adeline Duflot-Boukobza & Sarah Dumont & Eric Baudin & Suzette Delaloge & David Malka & Laurence Albiges & Patricia Pautier & Caroline , 2022. "Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial," Post-Print hal-03773192, HAL.
    2. Salah Ghabri & Erwan Autin & Anne-Isabelle Poullié & Jean Michel Josselin, 2018. "The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA)," Post-Print halshs-01683827, HAL.
    3. Salah Ghabri & Erwan Autin & Anne-Isabelle Poullié & Jean Michel Josselin, 2018. "The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA)," PharmacoEconomics, Springer, vol. 36(4), pages 407-417, April.
    4. Chloé Gervès-Pinquié & Fatima Daumas-Yatim & Benoît Lalloué & Anne Girault & Marie Ferrua & Aude Fourcade & François Lemare & Mario Dipalma & Etienne Minvielle, 2017. "Impacts of a navigation program based on health information technology for patients receiving oral anticancer therapy: the CAPRI randomized controlled trial," Post-Print hal-03150422, HAL.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Naghmeh Foroutan & Jean-Eric Tarride & Feng Xie & Fergal Mills & Mitchell Levine, 2019. "A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers," PharmacoEconomics - Open, Springer, vol. 3(4), pages 437-451, December.
    2. Florian Scotté & Etienne Minvielle & Olivier Mir & Fabrice André & Fabrice Barlesi & Jean-Charles Soria, 2020. "A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19–positive patients with cancer," Post-Print hal-02950441, HAL.
    3. Minvielle, E. & Fierobe, A. & Fourcade, A. & Ferrua, M. & di Palma, M. & Scotté, F. & Mir, O., 2023. "The use of patient-reported outcome and experience measures for health policy purposes: A scoping review in oncology," Health Policy, Elsevier, vol. 129(C).

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:26:y:2025:i:2:d:10.1007_s10198-024-01702-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.